Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO®. BLA has been approved by the USFDA".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has signed a partnership with Bioeq to commercialise NUFYMCO® in the United States. NUFYMCO® is an interchangeable biosimilar to Lucentis® (ranibizumab), which is widely used for treating serious eye conditions such as macular degeneration. The U.S. FDA has already approved the Biologics License Application (BLA) for the product. The deal gives Zydus a foothold in the lucrative U.S. ophthalmology biosimilars market through Bioeq's established commercial infrastructure.
This is a positive development for Zydus, adding a new revenue stream from the world's largest pharmaceutical market. The interchangeable biosimilar status is a strong commercial advantage, though the actual financial impact will depend on launch timelines and market share captured.